EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

284780

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at least four prior therapies. This includes patients whose disease failed to respond to at least two proteasome inhibitors, two immunomodulatory agents, and a CD38 inhibitor, and who showed disease progression on their last therapy. The recommendation was made by the Committee for Medicinal Products for…

You must be logged in to read/download the full post.